245 related articles for article (PubMed ID: 9537758)
1. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera.
Bondre VP; Sinha VB; Srivastava BS
FEMS Immunol Med Microbiol; 1997 Dec; 19(4):323-9. PubMed ID: 9537758
[TBL] [Abstract][Full Text] [Related]
2. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development.
Jonson G; Osek J; Svennerholm AM; Holmgren J
Infect Immun; 1996 Sep; 64(9):3778-85. PubMed ID: 8751929
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to the truncated (short) form of 'O' polysaccharides (TFOP) of Vibrio cholerae O139 lipopolysaccharides protect mice against experimental cholera induced by encapsulated O139 strains and such protection is mediated by inhibition of intestinal colonization of vibrios.
Nandy RK; Mukhopadhyay S; Ghosh AN; Ghose AC
Vaccine; 1999 Jul; 17(22):2844-52. PubMed ID: 10438055
[TBL] [Abstract][Full Text] [Related]
4. [Strains of Vibrio cholerae serogroups O1 and O139 that produce the basic protective antigens].
Smirnova NI; Livanova LF; Chekhovskaia GV; Eroshenko GA; Lazovskiĭ IuV; Zakharova TL
Zh Mikrobiol Epidemiol Immunobiol; 2000; (3):47-51. PubMed ID: 10925874
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.
Bishop AL; Schild S; Patimalla B; Klein B; Camilli A
Infect Immun; 2010 Oct; 78(10):4402-20. PubMed ID: 20679439
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of Vibrio cholerae O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates.
Singh DV; Matte MH; Matte GR; Jiang S; Sabeena F; Shukla BN; Sanyal SC; Huq A; Colwell RR
Appl Environ Microbiol; 2001 Feb; 67(2):910-21. PubMed ID: 11157262
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.
Eko FO; Schukovskaya T; Lotzmanova EY; Firstova VV; Emalyanova NV; Klueva SN; Kravtzov AL; Livanova LF; Kutyrev VV; Igietseme JU; Lubitz W
Vaccine; 2003 Sep; 21(25-26):3663-74. PubMed ID: 12922096
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
9. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
Boustanshenas M; Bakhshi B; Ghorbani M
J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
[TBL] [Abstract][Full Text] [Related]
10. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.
Kossaczka Z; Shiloach J; Johnson V; Taylor DN; Finkelstein RA; Robbins JB; Szu SC
Infect Immun; 2000 Sep; 68(9):5037-43. PubMed ID: 10948122
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.
Kossaczka Z; Szu SC
Glycoconj J; 2000 Jun; 17(6):425-33. PubMed ID: 11294508
[TBL] [Abstract][Full Text] [Related]
12. Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies.
Attridge SR; Holmgren J
Microb Pathog; 2009 Dec; 47(6):314-20. PubMed ID: 19818394
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic and vaccine significance of toxin-coregulated pili of Vibrio cholerae E1 Tor.
Attridge SR; Voss E; Manning PA
J Biotechnol; 1999 Aug; 73(2-3):109-17. PubMed ID: 10486921
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
Rijpkema SG; Jansen WH; Gielen H; Guinée PA
Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
[TBL] [Abstract][Full Text] [Related]
15. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
Yu X; Ma Q
Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
[TBL] [Abstract][Full Text] [Related]
16. Electrophoretic mobility and immune response of outer membrane proteins of Vibrio cholerae O139.
Pal S; Sasmal D; Guhathakurta B; Nair GB; Bhattacharya SK; Mallick R; Datta A
FEMS Immunol Med Microbiol; 1996 Sep; 15(2-3):143-8. PubMed ID: 8880140
[TBL] [Abstract][Full Text] [Related]
17. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the properties of Vibrio cholerae O139, O1 and other non-O1 strains.
Nandy RK; Sengupta TK; Mukhopadhyay S; Ghose AC
J Med Microbiol; 1995 Apr; 42(4):251-7. PubMed ID: 7707332
[TBL] [Abstract][Full Text] [Related]
19. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili.
Eko FO; Mayr UB; Attridge SR; Lubitz W
J Biotechnol; 2000 Sep; 83(1-2):115-23. PubMed ID: 11000467
[TBL] [Abstract][Full Text] [Related]
20. Cholera vaccines.
Ryan ET; Calderwood SB
Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
